Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients
Status:
Recruiting
Trial end date:
2022-10-25
Target enrollment:
Participant gender:
Summary
An open-label, 56 day, single-center, exploratory, proof-of-concept study of the anti-viral
effect of voclosporin (VCS) with an extended safety follow-up, up to 1 year. Study population
are adult KTRs with positive SARS-CoV-2 infection with mild to moderate symptoms. At study
entry, subjects are on standard therapy of dual immunosuppressive treatment of prednisone and
tacrolimus (TAC), following randomization, 10 out of 20 subjects will remain on this therapy
for the duration of the study, while the other 10 subjects will switch to VCS.